RxDoctor Payments Data

Howard Woodford, MD

Obstetrics & Gynecology · Florence, ALNPI 1952305799

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Antares Pharma, Inc. accounts for 65.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $340 and has fallen 67.5% since, to $110 in 2025. That places this record below the midpoint for obstetrics & gynecology clinicians in AL, where the typical reported total is $1,456.

$1,458in general payments, 2019–2025

Across 80 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$949
  • IBSA Pharma Inc.$99
  • Halozyme Inc$91
  • AbbVie$62
  • Novo Nordisk$51
  • Therapeuticsmd, Inc.$48
  • plus $157 from 8 others

What the payments were for

  • Food & beverage$1,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,458 in reported general payments places this provider in the 50th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama →

Medicare billing

Part B allowed, 2024
$1,892
Medicare patients
29
Services billed
2,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized545$25,731
Testosterone Cypionate122$6,406
Spironolactone85$2,321
Anastrozole336$1,359
Liothyronine Sodium13$801
Ezetimibe29$705
Levothyroxine Sodium37$554
Pravastatin Sodium30$247
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$82
Letrozole11$51
Zolpidem Tartrate14$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$55437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Florence

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →